169 related articles for article (PubMed ID: 33104907)
1. Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib.
Murachi Y; Sakai D; Koseki J; Inagaki C; Nishida N; Yamaguchi T; Satoh T
Int J Clin Oncol; 2021 Feb; 26(2):409-416. PubMed ID: 33104907
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
[TBL] [Abstract][Full Text] [Related]
3. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib.
Gökyer A; Küçükarda A; Köstek O; Hacıoğlu MB; Sunal BS; Demircan NC; Uzunoğlu S; Solak S; İşsever K; Çiçin I; Erdoğan B
Clin Transl Oncol; 2019 Nov; 21(11):1518-1523. PubMed ID: 30868388
[TBL] [Abstract][Full Text] [Related]
4. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.
Shiroyama T; Nagatomo I; Koyama S; Hirata H; Nishida S; Miyake K; Fukushima K; Shirai Y; Mitsui Y; Takata S; Masuhiro K; Yaga M; Iwahori K; Takeda Y; Kida H; Kumanogoh A
Sci Rep; 2019 Feb; 9(1):2447. PubMed ID: 30792455
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
[TBL] [Abstract][Full Text] [Related]
6. Sarcopenia, as Assessed by Psoas Cross-Sectional Area, Is Predictive of Adverse Postoperative Outcomes in Patients Undergoing Colorectal Cancer Surgery.
Richards SJG; Senadeera SC; Frizelle FA
Dis Colon Rectum; 2020 Jun; 63(6):807-815. PubMed ID: 32149784
[TBL] [Abstract][Full Text] [Related]
7. Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102.
Bekir Hacioglu M; Kostek O; Kurt N; Kucukarda A; Gokyer A; Ustabasioglu FE; Karatas F; Tuncbilek N; Uzunoglu S; Bilici A; Cicin I; Erdogan B
J BUON; 2019; 24(5):2198-2204. PubMed ID: 31786894
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of metastatic colorectal cancer patients treated with regorafenib in real-world practice].
Jiang ZC; Sun YK; Zhang W; Yang L; Cui CX; Wang HY; Zhang HG; Yihebali C; Zhou AP
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2018-2022. PubMed ID: 32654446
[No Abstract] [Full Text] [Related]
10. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
12. Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?
Erdoğan AP; Ekinci F; Karabaş A; Balçık OY; Barutça S; Dirican A
J Gastrointest Cancer; 2022 Mar; 53(1):45-51. PubMed ID: 33881720
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
[TBL] [Abstract][Full Text] [Related]
14. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
[TBL] [Abstract][Full Text] [Related]
16. The psoas muscle index distribution and influence of outcomes in an Asian adult trauma population: an alternative indicator for sarcopenia of acute diseases.
Tee YS; Cheng CT; Wu YT; Kang SC; Derstine BA; Fu CY; Liao CH; Su GL; Wang SC; Hsieh CH
Eur J Trauma Emerg Surg; 2021 Dec; 47(6):1787-1795. PubMed ID: 32277250
[TBL] [Abstract][Full Text] [Related]
17. Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial.
Pasqualetti G; Schirripa M; Dochy E; Fassan M; Ziranu P; Puzzoni M; Scartozzi M; Alberti G; Lonardi S; Zagonel V; Monzani F; Loupakis F
Eur J Cancer; 2020 Jul; 133():66-73. PubMed ID: 32446145
[TBL] [Abstract][Full Text] [Related]
18. Small bowel wall edema induced by regorafenib is associated with regorafenib intolerance and shorter survival in patients with metastatic colorectal cancer: A retrospective study.
Karakurt Eryılmaz M; Kerimoğlu Ü; Karaağaç M; Yalçın Müsri F; Araz M; Artaç M
J Oncol Pharm Pract; 2021 Dec; 27(8):1929-1935. PubMed ID: 33283629
[TBL] [Abstract][Full Text] [Related]
19. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
[TBL] [Abstract][Full Text] [Related]
20. Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib.
Watanabe D; Fujii H; Yamada Y; Matsuhashi N; Makiyama A; Iihara H; Takahashi T; Kiyama S; Kobayashi R; Yoshida K; Suzuki A
Int J Clin Oncol; 2021 Jul; 26(7):1257-1263. PubMed ID: 33839963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
